SCHEMBL18394896

SCHEMBL18394896

COC(=O)c1nc(Br)sc1N1CCOCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.48
▸ KDM4E B2RXH2 5/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ MAPT P10636 3/20 0.43
▸ HPGD P15428 3/20 0.43
▸ ALOX15 P16050 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ MGLL Q99685 1/20 0.40
▸ PIK3CA P42336 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18396188 0.86 ALDH1A1 (0.51) ALDH1A1KDM4EMAPK1SMN1; SMN2MAPT
SCHEMBL18394620 0.85 ALDH1A1 (0.49) ALDH1A1KDM4EMAPK1MAPTHPGD
SCHEMBL18412848 0.84 PIK3CA (0.42) ALDH1A1KDM4EMAPK1SMN1; SMN2MAPT
SCHEMBL18395143 0.81 ALDH1A1 (0.47) ALDH1A1KDM4EMAPK1SMN1; SMN2MAPT
SCHEMBL18394634 0.77 ALDH1A1 (0.46) ALDH1A1KDM4EMAPK1SMN1; SMN2MAPT
SCHEMBL10288078 0.77 ALDH1A1 (0.51) ALDH1A1KDM4EMAPK1SMN1; SMN2MAPT
SCHEMBL15157000 0.77 KCNH2 (0.44) ALDH1A1SMN1; SMN2MAPT
SCHEMBL15348861 0.74 PIK3CD (0.52) ALDH1A1KDM4EMAPK1SMN1; SMN2MAPT
SCHEMBL15356842 0.73 ALDH1A1 (0.48) ALDH1A1KDM4EMAPK1SMN1; SMN2MAPT
SCHEMBL20098347 0.73 ALDH1A1 (0.45) ALDH1A1KDM4ESMN1; SMN2MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-05-13 — — US disclosed
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-04-08 — — US disclosed
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors ENANTA PHARM INC (US) 2024-10-31 — — US disclosed
US-11952389-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2024-04-09 — — US disclosed
EP-3687543-B1 COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS ENANTA PHARM INC (US) 2024-03-20 — — EP disclosed
CN-111386118-B Combination pharmaceutical agents as RSV inhibitors 英安塔制药有限公司 2023-05-09 — — CN disclosed
US-20230087410-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARM INC (US) 2023-03-23 — — US disclosed
US-20220323460-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS ENANTA PHARM INC (US) 2022-10-13 — — US disclosed
US-11390631-B1 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2022-07-19 — — US disclosed
EP-3324977-B1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARM INC (US) 2022-07-13 — — EP disclosed
US-20190192535-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-06-27 — — US disclosed
US-20190192535-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-06-27 — — US disclosed
WO-2019067864-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2019-04-04 — — WO disclosed
WO-2019067864-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2019-04-04 — — WO disclosed
US-20180258102-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARM INC (US) 2018-09-13 — — US disclosed
EP-3324977-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS Enanta Pharmaceuticals, Inc. (US) 2018-05-30 — — EP disclosed
US-9957281-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2018-05-01 — — US disclosed
US-9957281-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2018-05-01 — — US disclosed
US-20170022221-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2017-01-26 — — US disclosed
WO-2017015449-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2017-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors GABRA5, GABRA1, GABBR2 ALDH1A1 621/4885KDM4E 1198/4885MAPK1 2860/4885
US-11952389-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 ALDH1A1 621/4885KDM4E 1198/4885MAPK1 2860/4885
US-11390631-B1 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 ALDH1A1 621/4885KDM4E 1198/4885MAPK1 2860/4885
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 ALDH1A1 621/4885KDM4E 1198/4885MAPK1 2860/4885
US-20220323460-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS SERPINB1, FURIN, HIF1AN ALDH1A1 3562/4885KDM4E 3876/4885MAPK1 2810/4885
US-20230087410-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS GABRA5, GABRA1, GABBR2 ALDH1A1 621/4885KDM4E 1198/4885MAPK1 2860/4885
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ACE, ACE2, SPCS3 ALDH1A1 4172/4885KDM4E 4059/4885MAPK1 1820/4885
US-20170022221-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS GABRA5, GABRA1, GABBR2 ALDH1A1 621/4885KDM4E 1198/4885MAPK1 2860/4885
US-20180258102-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS GABRA5, GABRA1, GABBR2 ALDH1A1 621/4885KDM4E 1198/4885MAPK1 2860/4885
US-20190192535-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS SERPINB1, FURIN, HIF1AN ALDH1A1 3562/4885KDM4E 3876/4885MAPK1 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback